← all works
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- The Lancet
- Topic
- Melanoma and MAPK Pathways
- Field
- Biochemistry, Genetics and Molecular Biology
- Canadian institutions
- Jewish General Hospital
- Funders
- GlaxoSmithKline
- Keywords
- DabrafenibDacarbazineMedicineInternal medicineMelanomaHazard ratioClinical endpointAdverse effectOncologyPhases of clinical researchProgression-free survivalClinical trialRandomized controlled trialGastroenterologySurgeryMetastatic melanomaChemotherapyCancerVemurafenibConfidence intervalCancer research
- Has abstract in OpenAlex
- no